{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:00:14Z","timestamp":1789466414213,"version":"build-2803163510"},"reference-count":78,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Metastatic breast cancer (MBC) remains incurable because of tumor evolution. Despite advances in targeted therapies\u2014CDK4\/6 inhibitors, PIK3 inhibitors, HER2-directed agents, and antibody\u2013drug conjugates\u2014median overall survival is modest, with resistance emerging in nearly all patients. From an evolutionary perspective, standard continuous maximum tolerated dose (MTD) therapy may create intense selective pressure that reduces treatment-sensitive cells and, in some incurable and resistance-prone settings, could permit competitive release of resistant clones. While MTD remains the guideline-endorsed standard of care in many metastatic settings and has produced substantial survival gains, the eco-evolutionary framework highlights a potential trade-off rather than a categorical failure of MTD. Cancer is not just a genetic disease but an evolving ecosystem where cell populations compete for limited resources. Resistant cells typically carry a fitness cost\u2014slower growth in the absence of treatment\u2014creating an exploitable vulnerability. By preserving treatment-sensitive cells through dose modulation or treatment holidays (adaptive therapy), we can harness competitive suppression to control resistant populations and prolong disease control, potentially doubling time to progression compared to continuous MTD. This primer translates these ideas into plain language for clinical trial application. We explain four core eco-evolutionary principles every breast oncologist should know, review emerging evidence from adaptive therapy trials in breast and other cancers, and discuss practical implementation strategies to incorporate into future trials. The goal is not cure through eradication, but long-term control through evolutionary management. These evolution-informed strategies may, in selected contexts, help delay resistance and prolong disease control, and represent a complementary framework that warrants prospective testing.<\/jats:p>","DOI":"10.3390\/cancers18182979","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:16:48Z","timestamp":1789460208000},"page":"2979","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eco-Evolutionary Thinking in Metastatic Breast Cancer: A Clinician\u2019s Primer on Why Tumors Outsmart Us and How to Fight Back Smarter"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-5934","authenticated-orcid":false,"given":"Aixa Elena","family":"Soyano","sequence":"first","affiliation":[{"name":"Department of Breast Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-8283","authenticated-orcid":false,"given":"Renee","family":"Brady-Nicholls","sequence":"additional","affiliation":[{"name":"Integrated Mathematical Oncology (IMO) Department, Moffitt Cancer Center, Tampa, FL 33612L, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem H.","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1621-1510","authenticated-orcid":false,"given":"Robert A.","family":"Gatenby","sequence":"additional","affiliation":[{"name":"Diagnostic Imaging and Interventional Radiology Department, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Robertson-Tessi","sequence":"additional","affiliation":[{"name":"Integrated Mathematical Oncology (IMO) Department, Moffitt Cancer Center, Tampa, FL 33612L, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Ataya","sequence":"additional","affiliation":[{"name":"Diagnostic Imaging and Interventional Radiology Department, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of Breast Cancer Mortality in the US-1975 to 2019","volume":"331","author":"Sun","year":"2024","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1245\/s10434-021-10227-3","article-title":"Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients","volume":"28","author":"Taskindoust","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: Past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kannan, K., Srinivasan, A., Kannan, A., and Ali, N. (2025). The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. Cancers, 17.","DOI":"10.20944\/preprints202507.2452.v1"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Roszkowska, M. (2024). Multilevel Mechanisms of Cancer Drug Resistance. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212402"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1158\/0008-5472.CAN-15-1337","article-title":"Application of Evolutionary Principles to Cancer Therapy","volume":"75","author":"Wojtkowiak","year":"2015","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"022404","DOI":"10.1103\/PhysRevE.99.022404","article-title":"Nonlinear adaptive control of competitive release and chemotherapeutic resistance","volume":"99","author":"Newton","year":"2019","journal-title":"Phys. Rev. E"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtbi.2018.07.028","article-title":"Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment","volume":"455","author":"West","year":"2018","journal-title":"J. Theor. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"188681","DOI":"10.1016\/j.bbcan.2022.188681","article-title":"Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes","volume":"1877","author":"Gedye","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e84263","DOI":"10.7554\/eLife.84263","article-title":"A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation","volume":"12","author":"West","year":"2023","journal-title":"eLife"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1005758127114","article-title":"Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long term follow-up of two Piedmont Oncology Association (POA) trials","volume":"42","author":"Kuss","year":"1997","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andre","year":"2023","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"188310","DOI":"10.1016\/j.bbcan.2019.188310","article-title":"Mechanisms of acquired tumor drug resistance","volume":"1872","author":"Aleksakhina","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.trecan.2023.05.001","article-title":"Clinical and translational relevance of intratumor heterogeneity","volume":"9","author":"Goyette","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"034407","DOI":"10.1103\/PhysRevE.108.034407","article-title":"Stochastic competitive release and adaptive chemotherapy","volume":"108","author":"Park","year":"2023","journal-title":"Phys. Rev. E"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","article-title":"Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies","volume":"78","author":"Gallaher","year":"2018","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"108891","DOI":"10.1016\/j.mbs.2022.108891","article-title":"Different costs of therapeutic resistance in cancer: Short- and long-term impact of population heterogeneity","volume":"352","author":"Kareva","year":"2022","journal-title":"Math. Biosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/0008-5472.CAN-12-2235","article-title":"Evolutionary approaches to prolong progression-free survival in breast cancer","volume":"72","author":"Silva","year":"2012","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/s41467-017-01516-1","article-title":"Spatial competition constrains resistance to targeted cancer therapy","volume":"8","author":"Bacevic","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/0008-5472.CAN-25-0351","article-title":"Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control","volume":"85","author":"Hockings","year":"2025","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1158\/0008-5472.CAN-20-4079","article-title":"Adaptive Therapy and the Cost of Drug-Resistant Mutants","volume":"81","author":"Wodarz","year":"2021","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kim, E., Brown, J.S., Eroglu, Z., and Anderson, A.R.A. (2021). Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. Cancers, 13.","DOI":"10.3390\/cancers13040823"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","article-title":"Towards Multidrug Adaptive Therapy","volume":"80","author":"West","year":"2020","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Thomas, D.S., Cisneros, L.H., Anderson, A.R.A., and Maley, C.C. (2022). In Silico Investigations of Multi-Drug Adaptive Therapy Protocols. Cancers, 14.","DOI":"10.3390\/cancers14112699"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104192","DOI":"10.1016\/j.critrevonc.2023.104192","article-title":"Adaptive therapy: A tumor therapy strategy based on Darwinian evolution theory","volume":"192","author":"Zhang","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20192454","DOI":"10.1098\/rspb.2019.2454","article-title":"Optimizing adaptive cancer therapy: Dynamic programming and evolutionary game theory","volume":"287","author":"Gluzman","year":"2020","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Seyedi, S., Teo, R., Foster, L., Saha, D., Mina, L., Northfelt, D., Anderson, K.S., Shibata, D., Gatenby, R., and Cisneros, L.H. (2024). Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16020257"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Brady-Nicholls, R., and Enderling, H. (2022). Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14215319"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, J., Gallaher, J., Cunningham, J.J., Choi, J.W., Ionescu, F., Chatwal, M.S., Jain, R., Kim, Y., Wang, L., and Brown, J.S. (2022). A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14215225"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102340","DOI":"10.1016\/j.ctrv.2022.102340","article-title":"Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours","volume":"104","author":"Crucitta","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/s41467-020-15596-z","article-title":"Exploiting evolutionary steering to induce collateral drug sensitivity in cancer","volume":"11","author":"Acar","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cell.2016.01.045","article-title":"Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution","volume":"165","author":"Zhao","year":"2016","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tips.2009.07.003","article-title":"Is resistance useless? Multidrug resistance and collateral sensitivity","volume":"30","author":"Hall","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","article-title":"Collateral sensitivity as a strategy against cancer multidrug resistance","volume":"15","author":"Pluchino","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"107342","DOI":"10.1016\/j.biotechadv.2019.01.009","article-title":"Collateral sensitivity of natural products in drug-resistant cancer cells","volume":"38","author":"Efferth","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2174\/1389557521666210112141455","article-title":"Anticancer Natural Products with Collateral Sensitivity: A Review","volume":"21","author":"Qian","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41598-017-00791-8","article-title":"Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer","volume":"7","author":"Dhawan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","article-title":"Toward a Better Understanding of the Complexity of Cancer Drug Resistance","volume":"56","author":"Gottesman","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/eva.12612","article-title":"Short- and long-term evolution in our arms race with cancer: Why the war on cancer is winnable","volume":"11","author":"Rosenheim","year":"2018","journal-title":"Evol. Appl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101114","DOI":"10.1016\/j.drup.2024.101114","article-title":"Cancer plasticity in therapy resistance: Mechanisms and novel strategies","volume":"76","author":"Niu","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.CAN-19-1941","article-title":"Eradicating Metastatic Cancer and the Eco-Evolutionary Dynamics of Anthropocene Extinctions","volume":"80","author":"Gatenby","year":"2020","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1158\/0008-5472.CAN-19-0807","article-title":"First Strike-Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction","volume":"79","author":"Gatenby","year":"2019","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.acr.2021.02.003","article-title":"Treatment-induced evolutionary dynamics in nonmetastatic locally advanced rectal adenocarcinoma","volume":"151","author":"Felder","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1158\/0008-5472.CAN-20-0806","article-title":"Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy","volume":"81","author":"Strobl","year":"2021","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients with Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/CCO.0000000000000905","article-title":"Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer","volume":"34","author":"Valenza","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/1078-0432.CCR-24-0651","article-title":"The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial","volume":"32","author":"Browne","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tegeler, C.M., Hartkopf, A.D., Banys-Paluchowski, M., Krawczyk, N., Fehm, T., and Jaeger, B.A.S. (2024). Circulating Tumor DNA in Early and Metastatic Breast Cance-Current Role and What Is Coming Next. Cancers, 16.","DOI":"10.3390\/cancers16233919"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Xu, J., Gao, H., Guan, X., Meng, J., Ding, S., Long, Q., and Yi, W. (2024). Circulating tumor DNA: From discovery to clinical application in breast cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1355887"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41467-025-56658-4","article-title":"Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay","volume":"16","author":"Elliott","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1038\/s41467-025-65432-5","article-title":"Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors","volume":"16","author":"Magbanua","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/1078-0432.CCR-20-1566","article-title":"The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer","volume":"27","author":"Jacob","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S1470-2045(26)00287-1","article-title":"Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): Extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"27","author":"Turner","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/0008-5472.CAN-25-0608","article-title":"Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy","volume":"86","author":"Liu","year":"2026","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/CCO.0000000000001168","article-title":"Liquid biopsy in breast cancer: Promises and challenges","volume":"37","author":"Loizidis","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"107035","DOI":"10.1016\/j.compbiomed.2023.107035","article-title":"Modeling the effect of acquired resistance on cancer therapy outcomes","volume":"162","author":"Masud","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"109522","DOI":"10.1016\/j.mbs.2025.109522","article-title":"Impacts of competition and phenotypic plasticity on the viability of adaptive therapy","volume":"389","author":"Vibishan","year":"2025","journal-title":"Math. Biosci."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhang, Y., Liu, X., and Liu, H. (2021). Optimizing Adaptive Therapy Based on the Reachability to Tumor Resistant Subpopulation. Cancers, 13.","DOI":"10.3390\/cancers13215262"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.bbagen.2019.06.007","article-title":"The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance","volume":"1863","author":"Bae","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100715","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41388-025-03582-y","article-title":"Adaptive cancer therapy: Can non-genetic factors become its achilles heel?","volume":"44","author":"Valcz","year":"2025","journal-title":"Oncogene"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2979\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:34:01Z","timestamp":1789461241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":78,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182979"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182979","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}